VRXA (Veraxa Biotech Holding AG) Piotroski F-Score: N/A (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRXA Veraxa Biotech Holding AG VRXA
6 GF Score
Price $1.77
! 2 Warning Signs
View Full Analysis

What is Veraxa Biotech Holding AG Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Veraxa Biotech Holding AG has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Veraxa Biotech Holding AG's Piotroski F-Score or its related term are showing as below:

Veraxa Biotech Holding AG  (NAS:VRXA) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Veraxa Biotech Holding AG Piotroski F-Score Related Terms


Veraxa Biotech Holding AG Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Veraxa Biotech Holding AG's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veraxa Biotech Holding AG Piotroski F-Score Chart

Veraxa Biotech Holding AG Annual Data
Trend Dec23 Dec24 Dec25
Piotroski F-Score
0.00 0.00 0.00

Veraxa Biotech Holding AG Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Piotroski F-Score 0.00 0.00 0.00 0.00 0.00

VRXA vs TTRX, IRD, IFRX: Piotroski F-Score Comparison

For the Biotechnology subindustry, Veraxa Biotech Holding AG's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veraxa Biotech Holding AG Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Veraxa Biotech Holding AG's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Veraxa Biotech Holding AG's Piotroski F-Score falls into.


VRXA
6GF Score
Veraxa Biotech Holding AG VRXA
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was $-83.59 Mil.
Cash Flow from Operations was $-12.43 Mil.
Revenue was $0.03 Mil.
Gross Profit was $0.02 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was (95.073 + 101.418) / 2 = $98.2455 Mil.
Total Assets at the begining of this year (Dec24) was $95.07 Mil.
Long-Term Debt & Capital Lease Obligation was $1.11 Mil.
Total Current Assets was $3.62 Mil.
Total Current Liabilities was $8.30 Mil.
Net Income was $-31.55 Mil.

Revenue was $0.00 Mil.
Gross Profit was $0.00 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was (106.31 + 95.073) / 2 = $100.6915 Mil.
Total Assets at the begining of last year (Dec23) was $106.31 Mil.
Long-Term Debt & Capital Lease Obligation was $0.79 Mil.
Total Current Assets was $6.29 Mil.
Total Current Liabilities was $2.86 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Veraxa Biotech Holding AG's current Net Income (TTM) was -83.59. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Veraxa Biotech Holding AG's current Cash Flow from Operations (TTM) was -12.43. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=-83.591/95.073
=-0.87922964

ROA (Last Year)=Net Income/Total Assets (Dec23)
=-31.553/106.31
=-0.29680181

Veraxa Biotech Holding AG's return on assets of this year was -0.87922964. Veraxa Biotech Holding AG's return on assets of last year was -0.29680181. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Veraxa Biotech Holding AG's current Net Income (TTM) was -83.59. Veraxa Biotech Holding AG's current Cash Flow from Operations (TTM) was -12.43. ==> -12.43 > -83.59 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=1.109/98.2455
=0.01128805

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=0.794/100.6915
=0.00788547

Veraxa Biotech Holding AG's gearing of this year was 0.01128805. Veraxa Biotech Holding AG's gearing of last year was 0.00788547. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=3.62/8.3
=0.43614458

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=6.288/2.856
=2.20168067

Veraxa Biotech Holding AG's current ratio of this year was 0.43614458. Veraxa Biotech Holding AG's current ratio of last year was 2.20168067. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Veraxa Biotech Holding AG's number of shares in issue this year was 141.408. Veraxa Biotech Holding AG's number of shares in issue last year was 141.408. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.019/0.029
=0.65517241

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Veraxa Biotech Holding AG's gross margin of this year was 0.65517241. Veraxa Biotech Holding AG's gross margin of last year was . ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=0.029/95.073
=0.00030503

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=0/106.31
=0

Veraxa Biotech Holding AG's asset turnover of this year was 0.00030503. Veraxa Biotech Holding AG's asset turnover of last year was 0. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+1+1+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Veraxa Biotech Holding AG has an F-score of 4 indicating the company's financial situation is typical for a stable company.


Veraxa Biotech Holding AG Business Description

Other Exchanges J8L0:Germany
Address Talacker 35, Zurich, CHE, 8001
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
6GF Score

Get the complete analysis for VRXA

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.77
Price